Silence Therapeutics and Mallinckrodt Announce Collaboration to Develop and Commercialize RNAi Therapeutics for Complement-mediated Diseases

LONDON and STAINES-UPON-THAMES, United Kingdom, Jul. 18 (Korea Bizwire) — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Silence Therapeutics plc (LON: SLN), a leader in the discovery, development and delivery of novel RNA2 interference (RNAi) therapeutics for the treatment of serious diseases, today announced a collaboration that will allow the companies to develop [...]